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Background: Human adenoviruses of species D (HAdV-D) can be associated with acute respiratory illness, epidemic
keratoconjunctivitis, and gastroenteritis, but subclinical HAdV-D infections with prolonged shedding have also been
observed, particularly in immunocompromised hosts. To expand knowledge on HAdV-D in Sub-Saharan Africa, we
investigated the prevalence, epidemiology and pathogenic potential of HAdV-D in humans from rural areas of 4
Sub-Saharan countries, Côte d’Ivoire (CI), Democratic Republic of the Congo (DRC), Central African Republic (CAR)
and Uganda (UG).
Methods: Stool samples were collected from 287 people living in rural regions in CI, DRC, CAR and UG. HAdV-D
prevalence and diversity were determined by PCR and sequencing. A gene block, spanning the genes pV to hexon,
was used for analysis of genetic distance. Correlation between adenovirus infection and disease symptoms,
prevalence differences, and the effect of age and gender on infection status were analyzed with cross tables and
logistic regression models.
Results: The prevalence of HAdV-D in the investigated sites was estimated to be 66% in CI, 48% in DRC, 28% in
CAR (adults only) and 65% in UG (adults only). Younger individuals were more frequently infected than adults; there
was no difference in HAdV-D occurrence between genders. No correlation could be found between HAdV-D
infection and clinical symptoms. Highly diverse HAdV-D sequences were identified, among which a number are
likely to stand for novel types.
Conclusions: HAdV-D was detected with a high prevalence in study populations of 4 Sub-Saharan countries. The
genetic diversity of the virus was high and further investigations are needed to pinpoint pathological potential of
each of the viruses. High diversity may also favor the emergence of recombinants with altered tropism and
pathogenic properties.
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Adenoviruses are non-enveloped icosahedral viruses with a
linear, double-stranded DNA genome that can cause a wide
spectrum of clinical diseases, including acute respiratory
illness, epidemic keratoconjunctivitis, acute hemorrhagic
cystitis, hepatitis, myocarditis and gastroenteritis [1,2].
Primary infection with human adenoviruses (HAdV)
or reactivation of persistent HAdV can lead to severe
systemic diseases in immunocompromised hosts, such as
bone marrow and solid organ transplant recipients and
patients with AIDS [3-5]. Based on serology, whole-
genome sequencing, and phylogenomics, eight HAdV
species (HAdV-A to -G) are differentiated within the
genus Mastadenovirus, comprising a total of 69 recognized
HAdV types. Most HAdV types belong to species D and
the majority of these HAdV-D types have been detected in
HIV-positive patients [6-8]. Knowledge about the patho-
genicity of HAdV-D types is limited. Types D8, D19, D37
and D54 are known to cause epidemic keratoconjunctivitis
[9-13]. The virulent type D53, a recombinant between D8,
D22, D37 and at least one unknown HAdV-D type, showed
a modified tropism and induced inflammation of the cor-
nea [14]. Another recombinant type, D56, was involved in
fatal pneumonia in a neonate and keratoconjunctivitis in
three adults [15]. Type D36 has been associated with obesity
in animals and humans [16] and types D65 and D67 were
detected in the stool of children with gastroenteritis [8,17].
The pathogenicity of the HAdV-D types frequently shed
by patients with AIDS remains controversial [3,18-20].
Prolonged fecal and urinary shedding of different HAdV-D
types and of recombinants has been observed [18,21].
Hence it has been proposed that recombination might
play a greater role in HAdV-D evolution than base substi-
tution [6]. Since HIV/AIDS as well as gastroenteritis are
common diseases in Sub-Saharan Africa and PCR-based
and sequence-confirmed studies on the prevalence of
HAdV-D in Sub-Saharan Africa are scarce [22,23], we ana-
lyzed the occurrence of HAdV-D in people from four Sub-
Saharan countries; the Côte d’Ivoire (CI), the Democratic
Republic of the Congo (DRC), the Central African Republic
(CAR), and Uganda (UG). We assessed possible connec-
tions between HAdV-D shedding and clinical symptoms or
demographic data, and in addition, we partially character-
ized the molecular isolates by comparison of minimum
genetic distances within the pV-hexon gene block.
Results
HAdV-D generic nested PCR and sequencing revealed a
HAdV-D prevalence of 66% (95% CI 56-76%) in CI, 48%
(95% CI 38-58%) in DRC, 28% (95% CI 13-51%) in CAR
(adults only), and 65% (95% CI 53-75%) in UG (adults only).
The prevalence in CI was significantly higher than in DRC
(P < 0.01). When comparing the adult populations in all four
countries, the prevalence in CI and UG was significantlyhigher than in DRC and CAR (p < 0.05). In CI and DRC
100% and 68% of the younger children and 71% and 50% of
the older children and adolescents were HAdV-D positive
(Table 1) and the proportion of infected people decreased
further to 64% and 39% in the adults in CI and DRC, re-
spectively. Overall there was a significant decrease in the
proportion of infected individuals with increasing age group
(regression coefficient -0.6, p < 0.05). Gender had no signifi-
cant effect on infection status (p > 0.100). The prevalence
per village ranged from 45-100% (data for individual villages
not shown) and there was overall no significant difference
between the villages (p > 0.05) (mean n/village = 16.7, range
2-38). The logistic regression model explained 11% of the
variance in the dataset (pseudo R-square = 0.1064).
To investigate the pathogenicity of HAdV-D, we tested
for a correlation between HAdV-D shedding and clinical
symptoms. Overall, 57% of the study participants reported
at least one clinical symptom. There was no correlation
between infection status and individual clinical signs, or
between infection status and poor health status, i.e. indi-
viduals that reported symptoms (p > 0.05) (Table 1).
We finally analyzed if the sequences of the current
study were derived from novel HAdV-D types. For this
purpose, we attempted to amplify a 4.8 kb fragment
spanning the genes pV-hexon gene block from 35 ran-
domly chosen, HAdV-D positive samples from CI,
DRC, CAR and UG. Fragments were obtained from 14
samples after 2nd or 3rd round of Long-Distance PCR
and completely sequenced. Thirteen different HAdV-D
sequences were obtained. Since in 2 samples from UG
close to identical sequences were identified, only one
of them (Hu4555_UG) was included in further analysis.
BLAST analysis of the hyper-variable Loop 2 region
from the 13 sequences revealed a pairwise identity of
86.4%-100% to known HAdV-D types (HAdV-D types
9, 13, 15, 17, 23, 25, 27, 29, 30, 32 47, 48, 56, 65, 67).
We then compared the minimum genetic distances
(minGD) of the pV-hexon sequences from 43 known
HAdV-D types with those of the 13 types identified in
this study. First, we determined minGD between the 43
recognized types (see Methods) to estimate the range
of intertypic minGD. 50% of all values lay between 0.02
and 0.05 nucleotide substitution per site (Figure 1).
Then, we determined minGD between the 13 sequences
generated in this study and any recognized type: here
84.6% of all values lay between 0.02 and 0.05 nucleotide
substitutions per site (Figure 1; Table 2). All 13 unique
sequences identified in this study exhibited minGD >0.02;
5 sequences even exhibited a minGD >0.04, which outper-
formed >50% of intertypic minGD (Figure 1; Table 2).
Comparable results were obtained by using estimated
instead of observed minGD (Table 2) and by analyzing
only the region containing the hyper-variable hexon
loops (Loops 1 and 2). These loops represent the major
Table 1 Human adenovirus species D (HAdV-D) detection and clinical symptoms
Number of analysed
individuals
% analysed
individuals
Number of HAdV-D
positive individuals
% HAdV-D positive
individuals
Côte d’Ivoire
Study group 95 100 63 66
0-5 years 4 4 4 100
6-19 years 7 7 5 71
20-77 years 84 88 54 64
Male 42 44 30 71
Female 53 56 34 63
Asymptomatic 45 47 15 33
Symptomatic 50 53 35 70
Abdominal pain 21 22 14 67
Diarrhea 3 3 3 100
Nausea 1 1 1 100
Ocular disease 6 6 3 50
Fever 10 11 9 90
Respiratory disease 8 8 6 75
Headache 19 20 12 63
Democratic Republic of the Congo
Study group 105 100 50 48
0-5 years 19 18 13 68
6-19 years 30 29 15 50
20-78 years 56 53 22 39
Male 51 49 27 53
Female 54 51 23 43
Asymptomatic 41 39 36 88
Symptomatic 64 61 27 42
Abdominal pain 46 44 18 39
Diarrhea 4 4 0 0
Nausea 1 1 0 0
Ocular disease 0 0 0 0
Fever 9 9 3 33
Respiratory disease 18 17 8 44
Headache 14 13 6 43
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are particularly prone to recombination events and are
among the target sequences for the characterization of
HAdV types. Although more sequence information would
be desirable, our data already point at 5 of 13 unique
sequences likely representing novel types (under the
conservative assumption that intertypic minGD> intratypic
minGD in at least 50% cases). Recombination analysis
of our data confirmed the tendency of HAdV-D to re-
combine in the hyper-variable loop region of the hexon
gene (data not shown).Discussion
In this study, we estimated a relatively high prevalence
of HAdV-D in several rural study populations in Sub-
Saharan countries. The overall prevalence in CI was
significantly higher than in DRC, which was also reflected
by the fact that the proportion of HAdV-D individuals
across all age classes was higher in CI compared to DRC
(Table 2). UG also had a particularly high prevalence when
comparing the adult population only. Since we were able
to explain only 11% of the variance in the dataset with the
model, there are likely to be many factors that influence
minGD study
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Figure 1 Comparison of observed minimum genetic distances.
In this strip-chart, observed minimum genetic distances (minGD) of
human adenovirus species D (HAdV-D) types are plotted. Left panel:
minGD was determined for the 13 HAdV-D sequences of this study
in relation to 43 HAdV-D types from Genbank. Right panel: minGD
was determined for every HAdV-D type from Genbank in relation to
the other 42 Genbank types. The red lines indicate the first quartile
(25%) at 0.02 and the third quartile (75%) at 0.05 of the minGD
values from the 43 Genbank types. The interquartile range (0.05-0.02)
gives the range of the middle 50% of the observed minGD values of
the Genbank types.
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been included in this study. Considering the fecal-oral
nature of HAdV transmission, such factors may be
sources of local water supply and hygiene measures in-
cluding toilet facilities. Also, nutrition and the local oc-
currence of HIV and other infections might play a role
in the susceptibility to, and shedding of, HAdV-D. HIV
prevalence was not determined for the populations in
the present study, but it is possible to speculate that the
high prevalence in CI is partly a result of the relatively
high HIV-1 prevalence in the Tai area (7.2%) [24].
Various sampling strategies and detection methods
limited the feasibility of direct comparison of our cross-
sectional study to other studies (Additional file 1: Table S1)
[22,23,25-35]. Study participants were within limited
age groups, showed specific symptoms and/or different
life styles. Contrary to other studies, we applied a gen-
eric nested PCR using non-degenerate primers that
target the hexon gene of all known HAdV-D types and
sequenced all positive samples. Most primers imple-
mented in other studies were degenerate and targeted
several HAdV species and if HAdV were confirmed by
sequencing, this was only performed for a selection ofsamples (Additional file 1: Table S1). This might have
resulted in a considerable underestimation of the HAdV-D
prevalence.
Our study included participants of all age groups ranging
from young children, older children/adolescents to adults.
We were able to detect that younger individuals shed
HADV-D significantly more frequently, which shows on
one hand that exposure to this infection likely occurs
early in life and on the other hand that adults might
develop immunity leading to a reduction in HAdV-D
shedding. It is not clear, whether this high prevalence
can be explained by a general high sensitivity of children to
any infection, or by a more likely ingestion of contaminated
material in young children compared to adults. Although
mothers should in theory be at higher risk of getting infec-
tion through baby care, no difference between men and
women regarding HAdV-D shedding was observed. This
could indicate that the majority of infections occur via
generally available sources in the villages.
It has been shown that some HAdV-D types induce
specific symptoms [8,9,14,16,17]. In our study, HAdV-D
sequences could not be finally assigned to specific HAdV-D
types, which makes it less likely to find a correlation be-
tween HAdV-D infection and an individual symptom.
In addition, the symptoms induced by HAdV-D types
are not pathognomonic and can be associated with dif-
ferent pathogens. To determine the effect of specific
HAdV-D types, it would be necessary, to exclude other
pathogens causing similar symptoms and to perform
type-specific laboratory analyses.
We analyzed genetic distances to further characterize
the HAdV-D types involved in this study. Historically,
novel AdV types have been determined using serological
assays based on recognition of specific epitopes on the
viral capsid and on biological properties (oncogenic, hae-
magglutinating and morphological properties). Nowadays,
phylogenetic analyses of complete sequences of the capsid
proteins, hexon, fiber and penton base, have been shown
to be good predictors for new types and for detection of
recombination events [36-38]. We analyzed a 4.8 kb long
sequence comprising the pV-hexon gene block. Molecular
divergence within the hexon protein, the most significant
protein for classification and recognition of types, can be
used to estimate whether sequences are likely to represent
novel AdV types [39,40]. Sequencing of the hyper-variable
Loop 2 region of the hexon gene has been proposed to be
sufficient for HAdV-typing [39]. For HAdV-D, a genetic
divergence ranging from 0.3 to 2,7% has been reported
[40]. Although analysis of the pV-hexon sequence alone
does not permit definite typing of HAdV-D, since recom-
bination may have occurred in other genes, comparison of
minimum genetic distances between recognized types and
the study sequences strongly suggested that novel HAdV-D
types are involved in our study (Figure 1; Table 2).
Table 2 Comparison of the minimum genetic distance values of HAdV-D types
Sample
Observed genetic distances Estimated genetic distances
pV-hexon gene Hypervariable loops pV-hexon gene Hypervariable loops
minGD
study
n minGD
Genbank
% minGD
Genbank
minGD
study
n minGD
Genbank
% minGD
Genbank
minGD
study
n minGD
Genbank
% minGD
Genbank
minGD
study
n minGD
Genbank
% minGD
Genbank
< < < < < < < <
minGD
study
minGD
study
minGD
study
minGD
study
minGD
study
minGD
study
minGD
study
minGD
study
Hu4751_CI 0.02 4 9.30 0.00 6 13.95 0.02 4 9.30 0.00 0 0.00
Hu4806_CI 0.02 13 30.23 0.03 11 25.58 0.02 10 23.26 0.02 11 25.58
Hu4719_CI 0.02 13 30.23 0.04 13 30.23 0.02 10 23.26 0.04 11 25.58
Hu4787_CI 0.03 15 34.88 0.06 18 41.86 0.03 13 30.23 0.07 13 30.23
Hu4152_DRC 0.03 16 37.21 0.04 13 30.23 0.03 13 30.23 0.06 13 30.23
Hu4813_CI 0.03 16 37.21 0.02 10 23.26 0.03 13 30.23 0.01 11 25.58
Hu4882_CI 0.03 16 37.21 0.07 18 41.86 0.04 17 39.53 0.11 19 44.19
Hu4746_CI 0.03 16 37.21 0.07 18 41.86 0.03 16 37.21 0.25 22 51.16
Hu4109_DRC 0.04 22 51.16 0.12 20 46.51 0.05 22 51.16 0.26 22 51.16
Hu4108_DRC 0.05 26 60.47 0.11 20 46.51 0.05 22 51.16 0.13 20 46.51
Hu4564_UG 0.05 31 72.09 0.12 20 46.51 0.06 29 67.44 0.29 22 51.16
Hu4214_DRC 0.06 37 86.05 0.17 33 76.74 0.07 34 79.07 0.67 35 81.40
Hu4555_UG 0.06 37 86.05 0.16 26 60.47 0.07 37 86.05 0.50 31 72.09
minGD study: minimum genetic distance determined for the 13 HAdV-D sequences of this study in relation to 43 HAdV-D types from Genbank; minGD Genbank:
minimum genetic distance determined for every HAdV-D type from Genbank in relation to the other 42Genbank types; CI: Côte d`Ivoire; DRC: Democratic Republic
of the Congo; UG: Uganda.
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This study shows that HAdV-D is prevalent in rural
populations across Sub-Saharan Africa, and that the virus
is more frequently shed by younger than older individuals.
HAdV-D shedding could not be linked to disease symp-
toms, but specific types were not investigated. The diver-
sity of the virus was high, which may include pathogenic
variants and favor the emergence of recombinants with
altered tropism and pathogenic properties.
Methods
Subjects, sampling and statistical analysis
Between 2011 and 2012, we collected stool samples from
individuals who have lived in or next to the tropical rain
forest in Western (Taï National Park in CI) and Central
(Salonga National Park in DRC) Africa for several years.
The study populations were predominantly hunters,
livestock breeders and cultivators with (CI) or without
(DRC) regular contact to other populations. Volunteer
participants (93 male; 107 female) were recruited from
12 villages (CI, n = 8; DRC, n =4). Participants were be-
tween 0 and 77 years old (mean = 41) in CI, and be-
tween 0 and 78 years old (mean = 28) in DRC. A basic
clinical examination was performed by a trained med-
ical professional and, when necessary, free treatment
and medical advice were provided. If treatment was not
possible on site, individuals were referred to an appropriatemedical facility. The final written medical history included
age, sex, location of residence, and information about
current medical condition. Participants were assigned to
one of three age groups: young children (0-5 years old),
older children and adolescents (6-19 years old), and adults
(20 year and older). The same sampling procedure was
applied in CAR and UG, where stool samples were col-
lected from adult male field assistants of Dzanga-Sangha
Protected Areas (CAR, n = 18) and Bwindi National Park
(Uganda, n= 69). Clinical data were not recorded for these 2
groups. Before sampling, the aim of the study, as well as the
possibility to quit the study at any point, was explained indi-
vidually in the local language. An individual study number
was assigned to every participant in order to protect the
privacy of the participant. Written informed consent was
obtained from every study participant before sampling
and the collection was approved by the responsible ethic
commission of every country and was performed accord-
ing to the declaration of Helsinki. The samples were con-
served in liquid nitrogen and later stored at -80°C. The
export to Germany occurred on dry ice with the appropri-
ate permissions. DNA extraction was performed using the
Qiagen and Roboklon stool kits, according to the manu-
facturer’s instructions.
Descriptive statistics, prevalence estimation and the
effects of demographic data were generated and analyzed
in Stata v12.0, using cross tables with Fischer exact tests
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status as dependent binomial factor and country, gender,
age group and village as independent factors. Results from
CAR and UG were used for prevalence estimation only.
Specific nested HAdV-D PCR
For the generic detection of members of the species
HAdV-D, non-degenerate primers were designed based on
an alignment of published HAdV-D sequences (Table 3).
These primers amplify a fragment of 354 bp in the
first round, and of 322 bp in the second round of PCR.
The target sequence lays at the end of the hexon gene
(position 20 194 - 20 547 in the genome of HAdV-D36;
Genbank accession number: GQ384080).The first round
of the nested PCR was performed with 5 μl of DNA
extracted from human feces as template, 12.7 μl of PCR
mix (containing 1× AmpliTaq™ buffer, 2,0 mM MgCl2, 5%
DMSO, dNTPs at 200 mM each, 2.0 units of AmpliTaq
Gold Polymerase (Applied Biosystems) and 1 μM of each
first round sense and antisense primer) and PCR-grade
H2O ad 25 μl. In second round amplification, 1.5 μl of the
first-round amplification product was added to 12.7 μl of
PCR mix with 1 μM of each second round primers and
H2O ad 25 μl. Thermocyclers of type TgradientS (Biometra,
Germany) were used under the following conditions: activa-
tion of the polymerase at 95°C for 12 min and 45 cycles of
denaturation (95°C, 30 s), annealing (63°C, 30 s), and elong-
ation (72°C, 2 min), final elongation at 72°C for 10 min.
All PCR products of expected size were purified and
sequenced with the Big Dye terminator cycle sequencing
kit (Applied Biosystems, Warrington, UK) on a 377 au-
tomated DNA sequencer (Applied Biosystems).
Specific long-distance-PCR
Long-Distance nested PCR was performed using the
TaKaRa-EX PCR system according to the instructions of
the manufacturer (Takara Bio Inc., Otsu, Japan) and re-
sulted in a fragment of 4.8 kb. The sense primers bind in
the 3′-end of the pVII gene and the antisense primers in
the 3′-end of the hexon gene (Table 3). The target se-
quence lays between positions 15 091 and 20547 of the
genome of HAdV-D36. Depending on the DNA concen-
tration, up to 7 μl of DNA, were added in the first round
to 15.5 μl of PCR mix (containing 10× ExTaq buffer with
MgCl2, dNTPs at 2.5 mM each, 5.0 units of Ex Taq Poly-
merase and 10 μM of each first round sense and antisense
primer) and PCR-grade H2O ad 50 μl. In second and third
round amplification, 1 μl of the reaction product generated
in the preceding PCR round, was added to 15.5 μl of PCR
mix with 10 μM of the respective primers and H2O ad
50 μl. Thermocyclers of type TgradientS (Biometra,
Germany) were used under the following conditions for
every round: activation of the polymerase at 94°C for 5 min
and 15 cycles of, followed by 15 cycles of denaturation(98°C, 20 s), annealing (60°C, 30 s), and elongation (68°C,
8 min + 5 s) and a final elongation at 72°C for 30 min.
All PCR products of expected size were purified and
sequenced as described above.
Sequence analysis
The 4.8 kb sequences determined in this study (n = 13)
were added to a data set consisting of sequences of the
pV-hexon gene block available in Genbank from completely
sequenced HAdV-D genomes (n = 43) (listed in Methods).
They were aligned with the ClustalW multiple alignment
method (EMBL, Heidelberg, Germany) (Alignment 1).
Another alignment was performed comprising only the
43 Genbank sequences (Alignment 2). In addition, the
hyper-variable loop regions of the hexon gene were ex-
tracted from alignments, resulting in the alignments 1a and
2a. Conserved blocks were selected from these alignments,
using Gblocks [41] as implemented in SeaView v4 [42].
This resulted in alignments of 4.556 (Alignment 1 and 2)
and 1.065 nucleotides (Alignment 1a and 2a). Observed
genetic distance matrices were obtained for every alignment
with the program Geneious v6.1.6 [43]. Evolutionary
distances were estimated using PAUP* v4.0 [44], based on
the best fitting nucleotide substitution model (GTR+ I +G),
as determined using jModeltest v2.1.3 [45].
In the observed and estimated genetic distance matrices
of the alignments 1 and 1a, the minimum genetic distance
(minGD) was determined for every sequence of this study
(minGD study 1-13) in relation to the 43 HAdV-D types
from Genbank. Correspondingly, in the observed and esti-
mated genetic distance matrix of alignment 2 and 2a the
minGD was defined for every HAdV-D type from Genbank
(minGD Genbank 1-43) in relation to the other 42 types.
Subsequently, we visualized the 13minGD study values and
the 43 minGD Genbank values in a strip chart (carried out
with R software) (Figure 1) and assessed for every minGD
study value the number and percentage of inferior minGD
Genbank values (Table 2).
Recombination analysis
With default settings in the Recombination Detection
Program v.4.16 (RDP4), recombination events, likely
parental isolates of recombinants and recombination
break points were analyzed using the RDP, GENECONV,
Chimaera, MaxChi and BOOTSCAN methods imple-
mented in the RDP4 program [46,47].
Genbank accession numbers of published adenovirus
sequences used for comparison of genetic distances
Genbank accession numbers AB448769; AJ854486;
JN226746; JN226747; AB562586; AF108105; AB448774;
JN226749; FJ404771; JN226750; JN226751; JN226752;
EF153474; JN226753; FJ824826; AB562587; JN226755;
JN226756; JN226758; GQ384080; DQ393829; AB448778;
Table 3 Primers for specific and long-distance PCR
PCR Gene HAdVspecies
1st-round primer (5′-3′) 2nd-round primer (5′-3′) 3rd-round primer (5′-3′) Annealing
temp. (C°)
Fragment
sizeSense Anti-sense Sense Anti-sense Sense Anti-sense
Generic PCR Hexon HAdV-D
AAGGCCGTCA
CCCTGCCCTT
GTGCGGCTGG
TGCACTCTGA
ACAACTCGGGCTTCACCGGC
GGCTGGTGCA
CTCTGACCACG
None None 63 322 bp
Long distance PCR PVII-Hexon HAdV-D
CGCCCAGCAA
TAACACCGGC
GTGCGGCTGG
TGCACTCTGA
GGCAGGACTCGCAGACGAGC
GGTGGGCTCA
TCCATGGGGT
GCGCGGAAAC
GTGTACTGGGT
GGGATGCGCC
ACATGACCCT
60 4.8 kb
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http://www.virologyj.com/content/11/1/25JN226759;JN226760; JN226761; JN226762; JN226763;
JN226764; AY875648; JN226757; EF153473; JN226765;
AB605240; AB333801; HM770721; HQ883276; JF799911;
JN162672; JN162671; JN935766; JQ326208; AP012285;
AP012302.
Genbank accession numbers of adenovirus sequences
determined in this study
hu4108_DRC: KF976521; hu4109_DRC: KF976522;
hu4214_DRC: KF976523; hu4152_DRC: KF976524;
hu4719_IC: KF976525; hu4746_IC: KF976526; hu4751_IC:
KF976527; hu4787_IC: KF976528; hu4806_IC: KF976529;
hu4813_IC: KF976530; hu4882_IC: KF976531; hu4555_UG:
KF976533; hu4557_UG: KF976532; hu4564_UG: KF976534.
Additional file
Additional file 1: Table S1. Published studies on adenovirus
prevalence in children with gastroenteritis.
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